Pfizer: Final data on pills to treat Covid-19 holds strong against hospitalization and death

Author : fannimobile
Publish Date : 2021-12-14 00:00:00


Pfizer: Final data on pills to treat Covid-19 holds strong against hospitalization and death

Pfizer's updated results for its experimental treatment for Covid-19 showed it cut the risk of hospitalization or death by 89% if given to high-risk adults within a few days of their first symptoms, the company announced in a news release Tuesday.

Pfizer hopes it can eventually offer the pills, under the name Paxlovid, for people to take at home before they get sick enough to go to the hospital. Paxlovid combines a new antiviral drug named nirmatrelvir and an older one called ritonavir.

After a month of follow-up, the study found five hospitalizations and no deaths among 697 people who received the drug within the first three days of symptoms. Among 682 who received placebo, 44 were hospitalized, including 9 who died. All of the adults in this study were unvaccinated.

If given within the first five days of symptoms, the efficacy was similar: 88%. These results hold up against a similar announcement from the company last month, when not all the data had come in yet.

The research also showed "an approximate 10-fold decrease in viral load at Day 5, relative to placebo," the statement said.

"This underscores the treatment candidate's potential to save the lives of patients around the world, whether they have been vaccinated or not," Pfizer CEO Dr. Albert Bourla said in a statement Tuesday. "Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic."
The company says it expects the drug to retain activity against variants like Omicron -- and it appears to do so in lab tests -- because the drug blocks an enzyme involved in viral replication. This is different from the spike protein on the virus' surface, whose numerous mutations have escalated the global concern around the variant.

Pfizer added that full study data are expected to be released later this month and submitted to a peer-reviewed publication.


Pfizer's updated results for its experimental treatment for Covid-19 showed it cut the risk of hospitalization or death by 89% if given to high-risk adults within a few days of their first symptoms, the company announced in a news release Tuesday.

Pfizer hopes it can eventually offer the pills, under the name Paxlovid, for people to take at home before they get sick enough to go to the hospital. Paxlovid combines a new antiviral drug named nirmatrelvir and an older one called ritonavir.

After a month of follow-up, the study found five hospitalizations and no deaths among 697 people who received the drug within the first three days of symptoms. Among 682 who received placebo, 44 were hospitalized, including 9 who died. All of the adults in this study were unvaccinated.

If given within the first five days of symptoms, the efficacy was similar: 88%. These results hold up against a similar announcement from the company last month, when not all the data had come in yet.

The research also showed "an approximate 10-fold decrease in viral load at Day 5, relative to placebo," the statement said.

"This underscores the treatment candidate's potential to save the lives of patients around the world, whether they have been vaccinated or not," Pfizer CEO Dr. Albert Bourla said in a statement Tuesday. "Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic."
The company says it expects the drug to retain activity against variants like Omicron -- and it appears to do so in lab tests -- because the drug blocks an enzyme involved in viral replication. This is different from the spike protein on the virus' surface, whose numerous mutations have escalated the global concern around the variant.

Pfizer added that full study data are expected to be released later this month and submitted to a peer-reviewed publication.


Pfizer's updated results for its experimental treatment for Covid-19 showed it cut the risk of hospitalization or death by 89% if given to high-risk adults within a few days of their first symptoms, the company announced in a news release Tuesday.

Pfizer hopes it can eventually offer the pills, under the name Paxlovid, for people to take at home before they get sick enough to go to the hospital. Paxlovid combines a new antiviral drug named nirmatrelvir and an older one called ritonavir.

After a month of follow-up, the study found five hospitalizations and no deaths among 697 people who received the drug within the first three days of symptoms. Among 682 who received placebo, 44 were hospitalized, including 9 who died. All of the adults in this study were unvaccinated.

If given within the first five days of symptoms, the efficacy was similar: 88%. These results hold up against a similar announcement from the company last month, when not all the data had come in yet.

The research also showed "an approximate 10-fold decrease in viral load at Day 5, relative to placebo," the statement said.

"This underscores the treatment candidate's potential to save the lives of patients around the world, whether they have been vaccinated or not," Pfizer CEO Dr. Albert Bourla said in a statement Tuesday. "Emerging variants of concern, like Omicron, have exacerbated the need for accessible treatment options for those who contract the virus, and we are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell the pandemic."
The company says it expects the drug to retain activity against variants like Omicron -- and it appears to do so in lab tests -- because the drug blocks an enzyme involved in viral replication. This is different from the spike protein on the virus' surface, whose numerous mutations have escalated the global concern around the variant.

Pfizer added that full study data are expected to be released later this month and submitted to a peer-reviewed publication.



Category :health

Imagine What Happened When You Dont Eat Sugar for 240 Days

Imagine What Happened When You Dont Eat Sugar for 240 Days

- No, You did not lose weight but reaped some serious health benefits. Yet, 75% of all our meals and beverages include added sugar.


Amazing Benefits And Uses of Quinoa For Humans

Amazing Benefits And Uses of Quinoa For Humans

- So, behind the word "quinoa" (or "quinoa" is the correct name, the options are also used: "rice quinoa", "Peruvian rice", "quinoa")


Top 10 Yoga Asana For Normal Delivery

Top 10 Yoga Asana For Normal Delivery

- It is often found that normal delivery is more beneficial for both you and your baby than a Cesarean.


Melon Surprising Benefits And Amazing Uses For Humans

Melon Surprising Benefits And Amazing Uses For Humans

- One cup of cantaloupe chunks provides 34% of your daily value for vitamin C to support blood vessels



Category